Tempest Therapeutics Inc.

0.72
-0.04 (-5.25%)
At close: Apr 03, 2025, 3:59 PM
0.73
1.32%
Pre-market: Apr 04, 2025, 04:54 AM EDT
-5.25%
Bid 0.7
Market Cap 32.6M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -1.5
PE Ratio (ttm) -0.48
Forward PE -0.82
Analyst Buy
Ask 0.74
Volume 507,011
Avg. Volume (20D) 813,171
Open 0.71
Previous Close 0.76
Day's Range 0.70 - 0.73
52-Week Range 0.70 - 5.31
Beta -2.28

About TPST

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops T...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 12, 2012
Employees 24
Stock Exchange NASDAQ
Ticker Symbol TPST
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for TPST stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 876.56% from the latest price.

Stock Forecasts
4 months ago
-10.5%
Tempest Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
7 months ago
+30.25%
Tempest Therapeutics shares are trading higher after the company announced feedback from its end-of-Phase 2 meeting with the FDA for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma.